The Medicine

Discovering therapies that effectively improve lives of patients with Hepatitis C.

The Approach

Building greater transparency to facilitate access to our medicines.

The Response

Committed to making a difference in the lives of those who are living with the virus.

HCV-MP is a division of Mash-Premiere pharmaceutical company, with innovation power aiming to develop innovative products to enhance health outcomes of Hepatitis C patients.


(Sofosbuvir 400 mg)


(Daclatasvir 60 mg)

Sofolanork Plus

(Sofosbuvir 400 mg
Ledipasvir 90 mg)


We are leaders in the development and production of innovative products that are based on research mechanisms. Our products differ with respect to their development and production, and thus the level of expertise, know-how and technologies required.

Clinical Trials

Clinical studies are conducted to determine whether a new treatment is safe. Such studies are based on healthy volunteers and patients who agree to participate and try new medicines. They are fundamental to the development of innovative medicines that treat Hep C…

Clinical Trials
Focus on Results

Focus on Results

We are committed to investing in valuable, innovative technologies that improve the cost-effectiveness of treatment and help examine individual response to treatment…


We are striving to adapt to the evolving needs of society and contribute to promote the well-being of communities and wellness of the environment…


As a part of a leader pharmaceutical company, we are pledged to deliver on our commitments to our patients, customers, employees, communities, partners and to our environment. Our Success is ultimately measured by the difference we make to improve people’s lives…